# Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

> **NCT04447651** · — · ACTIVE_NOT_RECRUITING · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Solid Tumor
- SF3B1 Gene Mutation
- Spliceosome Mutation
- U2AF1 Gene Mutation
- SRSF2 Gene Mutation

## Interventions

- **OTHER:** Recommendation for treatment with immunotherapy

## Key facts

- **NCT ID:** NCT04447651
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-09-17
- **Primary completion:** 2023-05-15
- **Final completion:** 2026-08
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04447651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04447651, "Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT04447651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*